Delivering a therapy to kerb COVID-19
Sheraz Gul explores current research developments to help treat and tackle the spread of COVID-19.
List view / Grid view
Articles
The Crick HTS facility – facilitating research through large-scale screening
The high-throughput screening (HTS) facility at the Francis Crick Institute in the UK provides a core service for Crick research groups. It enables scientists to use large-scale, unbiased screening technologies and approaches as part of their research. Nikki Withers spoke to the Science Technology Platform Head, Michael Howell, to hear…
High-throughput screening as a method for discovering new drugs
High-throughput screening is a common method of identifying lead compounds for drug development. The most common targets are enzymes – catalytic proteins that perform chemical reactions in the cell. In this article, Matthew Lloyd discusses the opportunities and challenges associated with this approach.
If Columbus had a map… guiding the discovery of new drugs
Exploring large databases and selecting compounds of interest can be extremely time-consuming for researchers. Here, Sacha Javor, Horst Flotow and Jingwen Shi discuss a novel chemoinformatics approach for drug discovery.
Current state of NAFLD treatments and the promise of in vitro platforms towards better screening of drug candidates
The heterogeneous pathogenesis of metabolic fatty liver diseases presents researchers with numerous challenges when trying to develop a treatment. This article explores the spectrum of these diseases and presents a novel in vitro platform for screening drug candidates.
Triplet immuno-oncology drug combinations – the future of treating multiple cancer
The oncology market is saturated with new drugs that target the immune system, however, these only target part of the problem caused by cancer’s ability to hide from the immune system. Miguel Ferreira discusses why emerging three-drug combinations are poised to redefine the immuno-oncology treatment paradigm in advanced malignancies with…
Neoantigens: presenting new vaccine opportunities in immuno-oncology
Neoantigens have gained much interest in recent years, mainly due to their ability to elicit a strong, specific immune response. Nikki Withers spoke to two immunology experts to explore the progress being made and assess what remains challenging for cancer investigators working on these transformational therapies.
Using scientific literature to aid the development of a safe and effective COVID-19 vaccine
Researchers in the US describe how they utilised previously published scientific literature to guide the design of their potential COVID-19 vaccine.
Expert view: GenScript’s unique four-tier platform for successful synthesis of challenging neoantigen peptides for precision medicine
Despite hundreds of off-the-shelf treatments, cancer remains the second leading cause of death globally.
Expert view: Delivering better therapeutics: fully characterising and recovering T cells
T cell-based therapies have shown promise as new treatment options for various cancers.
Expert view: From 3D high throughput to simple automated imaging: cellular imaging within reach of every laboratory
Our Ability to image cells has come a long way since the pioneering days of Galileo Galilei and Antonie van Leeuwenhoek.
Expert view: High-throughput analytics for smarter cell-line development
Combine titer and glycan screening during clone selection and cell culture optimisation to make more informed choices sooner, significantly reducing the development time for therapeutic antibodies.
Expert view: CRISPR screening: a powerful approach to drug discovery and development
CRISPR screening utilises the power and precision of CRISPR-Cas9 gene editing to reveal and validate novel drug targets or to study the underlying causes of disease.
Expert view: Finding a translatable disease model suitable for drug discovery screening
Effective drug discovery and development greatly relies on the availability of predictive pre-clinical models.
Using pharmacologically-established medicines to treat COVID-19
A new suggestion has highlighted that the available pharmacologically-established existing medicines should be used to combat COVID-19.
